Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.46 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788387 | 0.87 | HDAC8 (0.46) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL1964418 | 0.87 | HDAC8 (0.46) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL2636531 | 0.83 | HDAC1 (0.36) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL25383658 | 0.81 | MAPT (0.49) | HDAC1NOTUMHDAC6HDAC8 | |
| SCHEMBL640675 | 0.80 | CES2 (0.50) | KCNQ3KCNQ2KCNE1KCNQ1HDAC1 | |
| SCHEMBL30506215 | 0.80 | CES2 (0.50) | KCNQ3KCNQ2KCNE1KCNQ1HDAC1 | |
| SCHEMBL1739428 | 0.80 | P4HB (0.42) | KIF11HDAC1NOTUMHDAC6HDAC8 | |
| SCHEMBL2562099 | 0.80 | KIF11 (0.44) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL25384738 | 0.77 | HDAC1 (0.38) | KIF11HDAC1NOTUMHDAC6HDAC8 | |
| SCHEMBL20580082 | 0.77 | SNCA (0.46) | HDAC1HDAC6CYP11B1CYP11B2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-03-23 | — | — | US | disclosed |
| EP-4081509-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Zydus Lifesciences Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| CN-114901640-A | Novel compounds useful for the treatment of dyslipidemia | 兹杜斯生命科学有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021130723-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089247-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | PCSK9, CETP, LCAT | KIF11 1612/4885KCNQ3 2472/4885KCNQ2 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.